260 related articles for article (PubMed ID: 11735161)
1. Arsenic trioxide: its role in acute promyelocytic leukemia and potential in other hematologic malignancies.
Tallman MS
Blood Rev; 2001 Sep; 15(3):133-42. PubMed ID: 11735161
[No Abstract] [Full Text] [Related]
2. Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies.
Douer D; Tallman MS
J Clin Oncol; 2005 Apr; 23(10):2396-410. PubMed ID: 15800332
[TBL] [Abstract][Full Text] [Related]
3. Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia?
Verstovsek S; Giles F; Quintás-Cardama A; Perez N; Ravandi-Kashani F; Beran M; Freireich E; Kantarjian H
Hematol Oncol; 2006 Dec; 24(4):181-8. PubMed ID: 16783836
[TBL] [Abstract][Full Text] [Related]
4. Clinical usefulness of arsenic trioxide in the treatment of acute promyelocytic leukemia.
Lo Coco F
Haematologica; 2002 May; 87(5):452-3. PubMed ID: 12010655
[No Abstract] [Full Text] [Related]
5. Use of arsenic trioxide in haematological malignancies: insight into the clinical development of a novel agent.
Amadori S; Fenaux P; Ludwig H; O'dwyer M; Sanz M
Curr Med Res Opin; 2005 Mar; 21(3):403-11. PubMed ID: 15811209
[TBL] [Abstract][Full Text] [Related]
6. Advances in management of acute promyelocytic leukemia with arsenic trioxide.
Ma J
Chin J Integr Med; 2007 Jun; 13(2):92-4. PubMed ID: 17609904
[No Abstract] [Full Text] [Related]
7. Arsenic trioxide in the management of acute promyelocytic leukaemia.
Mathews V; Chandy M; Srivastava A
Natl Med J India; 2001; 14(4):215-22. PubMed ID: 11547528
[TBL] [Abstract][Full Text] [Related]
8. [Pharmacological and clinical properties of arsenic trioxide (Trisenox) for relapse or refractory acute promyelocytic leukemia therapy].
Tajima M
Nihon Yakurigaku Zasshi; 2005 Jun; 125(6):389-96. PubMed ID: 16079563
[No Abstract] [Full Text] [Related]
9. Treatment of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide: review of clinical and basic studies.
Liu P; Han ZC
Int J Hematol; 2003 Jul; 78(1):32-9. PubMed ID: 12894848
[TBL] [Abstract][Full Text] [Related]
10. [Arsenic trioxide: "a successful poison" in patients with acute promyelocytic leukemia].
Lengfelder E; Schultheis B; Büchner T; Hehlmann R
Dtsch Med Wochenschr; 2007 Feb; 132(7):330-6. PubMed ID: 17286223
[No Abstract] [Full Text] [Related]
11. Arsenic trioxide in acute promyelocytic leukemia: potion not poison.
Powell BL
Expert Rev Anticancer Ther; 2011 Sep; 11(9):1317-9. PubMed ID: 21929304
[No Abstract] [Full Text] [Related]
12. Acute promyelocytic leukemia: new issues on pathogenesis and treatment response.
Vitoux D; Nasr R; de The H
Int J Biochem Cell Biol; 2007; 39(6):1063-70. PubMed ID: 17468032
[TBL] [Abstract][Full Text] [Related]
13. Comparing two arsenic trioxide administration methods in APL therapy.
Zhou J; Meng R; Yang BF
Chin Med J (Engl); 2004 Sep; 117(9):1411-3. PubMed ID: 15377438
[No Abstract] [Full Text] [Related]
14. Evidence for basophilic differentiation of acute promyelocytic leukaemia cells during arsenic trioxide therapy.
Masamoto Y; Nannya Y; Arai S; Koike Y; Hangaishi A; Yatomi Y; Kurokawa M
Br J Haematol; 2009 Mar; 144(5):798-9. PubMed ID: 19036092
[No Abstract] [Full Text] [Related]
15. Successful pregnancy after arsenic trioxide therapy for relapsed acute promyelocytic leukaemia.
Ammatuna E; Cavaliere A; Divona M; Amadori S; Scambia G; Lo-Coco F
Br J Haematol; 2009 Aug; 146(3):341. PubMed ID: 19545283
[No Abstract] [Full Text] [Related]
16. [Arsenic trioxide as a therapeutic agent in APL].
Emi N
Nihon Rinsho; 2007 Jan; 65 Suppl 1():724-8. PubMed ID: 17474483
[No Abstract] [Full Text] [Related]
17. Arsenicals in hematologic cancers.
Novick SC; Warrell RP
Semin Oncol; 2000 Oct; 27(5):495-501. PubMed ID: 11049017
[TBL] [Abstract][Full Text] [Related]
18. Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement.
Knipp S; Gattermann N; Schapira M; Käferstein H; Germing U
Leuk Res; 2007 Nov; 31(11):1585-7. PubMed ID: 17416415
[TBL] [Abstract][Full Text] [Related]
19. Hyperleukocytosis from arsenic trioxide.
Levy M; Wofford MM; Powell BL; McLean TW
Pediatr Blood Cancer; 2008 Jun; 50(6):1265-7. PubMed ID: 18300308
[TBL] [Abstract][Full Text] [Related]
20. Arsenic trioxide as a treatment for myelodysplastic syndrome.
Sekeres MA
Curr Hematol Rep; 2005 Jan; 4(1):59-63. PubMed ID: 15610661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]